NDAOPHTHALMICSOLUTION/DROPS
Approved
Apr 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
VIGAMOX (moxifloxacin hydrochloride) by Teva is 12. Approved for bacterial conjunctivitis, bacterial infections, eye infections. First approved in 2003.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIGAMOX (moxifloxacin hydrochloride) is a fluoroquinolone antibiotic ophthalmic solution used to treat bacterial eye infections including conjunctivitis and post-operative endophthalmitis. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death. The drug is well-absorbed with approximately 90% bioavailability and demonstrates no phototoxicity risk compared to other fluoroquinolones.
$0.167BPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with modest Part D spending indicates a consolidating ophthalmic antibiotic franchise; teams focus on managed care penetration and generic transition planning.
Mechanism of Action
12.1 Mechanism of Action Moxifloxacin hydrochloride is a member of the fluoroquinolone class of antibacterial agents [see ] . 12.2 Pharmacodynamics Photosensitivity Potential A study of the skin response to ultraviolet (UVA and UVB) and visible radiation conducted in 32 healthy volunteers (8 per…
Worked on VIGAMOX at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.